TAK$14.42
Chart
Performance
Key Stats
AI TAK Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralTakeda Pharmaceutical Company Limited shows a mixed investment profile. It benefits from a strong global presence and a diverse product pipeline, but faces some headwinds in terms of recent performance and market sentiment. The high dividend yield is attractive, but recent financial trends warrant caution.
Thematic
Takeda operates in the stable but competitive pharmaceutical sector. Key thematic drivers include advancements in rare diseases, oncology, and neuroscience. The company's focus on plasma-derived therapies and vaccines aligns with growing healthcare demands.
Fundamental
Takeda exhibits a solid financial position with significant assets and manageable debt, but recent profitability and revenue growth have been inconsistent. The high dividend yield is a notable positive.
Technical
The stock's recent performance shows a decline over the past month, though it has shown positive returns year-to-date and over 6 months. Technical indicators suggest a neutral to slightly bearish short-term outlook.
| Factor | Score |
|---|---|
| Rare Diseases & Specialty Care | 85 |
| Oncology Advancements | 75 |
| Neuroscience Innovation | 70 |
| Global Market Access | 80 |
| Biologics & Plasma-Derived Therapies | 70 |
| Factor | Score |
|---|---|
| Valuation | 35 |
| Profitability | 45 |
| Growth | 40 |
| Balance Sheet Health | 70 |
| Cash Flow | 75 |
| Dividends | 95 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 55 |
| Volume Confirmation | 65 |
| Support & Resistance | 70 |
| Short-term Performance | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Cash Flow Generation
The company generated positive free cash flow of $677.56 billion in Q1 2025, indicating robust operational cash generation to fund investments and operations.
Improving Net Margin
The net margin has increased from 6.4% in Q1 2022 to 7.9% in Q1 2023, and then to 3.4% in Q1 2024, showing improving profitability relative to revenue, though Q1 2025 saw a dip to -9.8%.
Bearish Points (7)
Significant EPS Surprise Miss
Q4 2024 EPS estimate was 87.45, but the reported EPS was 29.07, a miss of -66.76%, indicating a significant discrepancy between expected and actual earnings.
High P/E Ratio (TTM)
The TTM P/E ratio of 63.74 is quite high, especially considering the EPS of 0.23, suggesting the stock may be overvalued relative to its current earnings.
Calendar
March 2025
31
Ex-Dividend Date
July 2025
7
Next Dividend Date
July 2025
30
Next Earnings Date
H: $
A: $
L: $
H: 1232.15B
A: 1161.14B
L: 1092.00B
Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Seasonals
Price Target
16.89 USD
The 39 analysts offering 1 year price forecasts for TAK have a max estimate of 18.69 and a min estimate of 14.93.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major global pharmaceutical competitor to Takeda across various therapeutic areas, including oncology, rare diseases, and vaccines.
Weight: 94
Swiss multinational pharmaceutical company, a direct competitor in oncology, neuroscience, immunology, and rare diseases.
Weight: 93
Leading global pharmaceutical company with strong positions in oncology (Keytruda), vaccines, and hospital acute care, competing with Takeda in several therapeutic segments.
Weight: 92
Anglo-Swedish multinational pharmaceutical and biotechnology company, a significant competitor in oncology, cardiovascular, renal, and metabolism (CVRM), and respiratory diseases.